PARA vs SUPN · rev $5.0M vs rev $426.8M
PARA (PARA) versus Supernus Pharmaceuticals Inc (SUPN) — a side-by-side from cached financials, not a winner call.
PARA (PARA) common stock.
Supernus Pharmaceuticals Inc (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported PARA revenue for 2026-06-30 was $5.0M. Net income was -$13.4M. Revenue was up 84.3% from 2026-03-31 to 2026-06-30. PARA currently screens at market cap $0.
Latest reported SUPN revenue for 2026-06-30 was $426.8M. Net income was -$60.7M. SUPN currently screens at market cap $2.53B.
PARA currently screens at market cap $0. SUPN currently screens at market cap $2.53B.
Not investment advice. Open the PARA and SUPN stock pages for the full models.
Not investment advice.